Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW)
CUSIP: 68232V884
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common stock, par value $.01 per share
- Shares outstanding
- 8,133,373
- Total 13F shares
- 1,304,595
- Share change
- +41,108
- Total reported value
- $2,413,244
- Price per share
- $1.85
- Number of holders
- 18
- Value change
- +$101,966
- Number of buys
- 9
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68232V884:
Top shareholders of TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
|
— |
10%
|
886,887
|
$1,641,628 | +$632,468 | 30 Sep 2025 | |
| Viriom, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,645,100
|
$1,480,590 | — | 03 Apr 2024 | |
| ORBIMED ADVISORS LLC |
13D/G
13F
|
Company |
20%
|
760,824
|
$1,164,061 | $0 | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
4.1%
|
330,000
|
$488,400 | — | 30 Jun 2025 | |
| Alyeska Investment Group, L.P. |
13D/G
13F
|
Company |
9.9%
|
302,252
|
$462,446 | $0 | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.8%
|
149,800
|
$221,704 | — | 30 Jun 2025 | |
| Steven M. Fruchtman |
3/4/5
|
PRESIDENT, CHIEF EXECUTIVE OFF, Director |
—
mixed-class rows
|
121,014
mixed-class rows
|
$98,282 | — | 13 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.44%
|
35,725
|
$52,874 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.35%
|
28,493
|
$42,170 | — | 30 Jun 2025 | |
| Abraham N. Oler |
3/4/5
|
SVP Corp Dev & Gen Counsel |
—
mixed-class rows
|
96,197
mixed-class rows
|
$36,818 | — | 07 Feb 2022 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.21%
|
17,169
|
$25,410 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.2%
|
16,063
|
$23,773 | — | 30 Jun 2025 | |
| Mark Patrick Guerin |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
44,755
mixed-class rows
|
$23,400 | — | 05 Feb 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.16%
|
13,173
|
$19,496 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.12%
|
9,956
|
$14,735 | — | 30 Jun 2025 | |
| Mark S. Gelder MD |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
82,667
mixed-class rows
|
$13,847 | — | 13 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
3,006
|
$4,449 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
719
|
$1,064 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
706
|
$1,045 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
162
|
$240 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0%
|
102
|
$151 | — | 30 Jun 2025 | |
| Vermillion & White Wealth Management Group, LLC |
13F
|
Company |
0%
|
96
|
$142 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
94
|
$139 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
60
|
$89 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
2
|
$3 | — | 30 Jun 2025 | |
| TPAV, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
192,696
mixed-class rows
|
— | — | 02 Apr 2025 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
164,000
|
— | — | 16 Sep 2024 | |
| Victor M. Moyo |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
125,000
|
— | — | 02 Oct 2023 | |
| James J. Marino |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Jerome Groopman |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Peter Atadja |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Viren Mehta |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 |
Institutional Holders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) as of Q3 2025
As of 30 Sep 2025,
Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,304,595 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, TWO SIGMA INVESTMENTS, LP, HRT FINANCIAL LP, XTX Topco Ltd, and BlackRock, Inc..
This page lists
18
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
19
Q3 2025 holders
18
Holder diff
-1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.